Saisie de commande
Switzerland
Lien pour commandesContactUsLinkComponent
 

Affinity chromatography media, MabSelect™ PrismA

MabSelect™ PrismA, Liquid, 60 µm, 200 ml
Catalog # 17-5498-02
Supplier:   Cytiva
Affinity chromatography media, MabSelect™ PrismA
Catalog # 17-5498-02
Supplier:  Cytiva
CAS Number:  
Affinity chromatography media, MabSelect™ PrismA
Affinity chromatography media, MabSelect™ PrismA

MabSelect™ PrismA, Liquid, 60 µm, 200 ml

CAS Number:  
Price
6 300.00 SFr.
Log in for availability
1 * 200 mL
Product Details & Documents

MabSelect™ PrismA has been improved with an optimised high-flow agarose base matrix and a genetically engineered protein A-derived ligand, allowing future demands in mAb processing to be met.

  • Enhanced dynamic binding capacity allows high mass throughput of processed mAb per resin volume unit
  • Excellent alkaline stability enables efficient cleaning and sanitisation using 0,5 to 1,0 M NaOH for improved process economy, bioburden, control and robustness
  • Covered by a comprehensive security of supply program, including dual sources of the agarose base matrix and protein A ligand

MabSelect™ PrismA builds on the proven track record of MabSelect™ and MabSelect™ SuRe™ resins in commercial mAb production.

Specifications

Specifications

  • Granulométrie:
    60 µm
  • Cdt:
    200 ml
  • Désignation:
    MabSelect™ PrismA
  • Type:
    Liquid
  • Plage de pH:
    3 – 12
  • Cat. No.:
    17-5498-02
  • Matrice:
    Rigid, highly cross-linked agarose
  • Méthode de couplage de ligands:
    Epoxy
  • Ligand:
    Alkaline-stabilised protein A-derived (E.coli)
  • Capacité de fixation:
    ~ 40 mg polyclonal IgG/ml resin, 2 min residence time<br />~ 80 mg polyclonal IgG/ml resin, 6 min residence time
  • Température de stockage:
    2 - 8 °C

Specifications

Recommendations

Recommendations will be personalized based on your shopping preferences only if you have given your consent by enabling "Enhance my Shopping Experience" on the "Personal Info page".

Otherwise, you will receive generic recommendations.